[go: up one dir, main page]

MA28017A1 - Compositions ophtalmiques traitant l'hypertention oculaire - Google Patents

Compositions ophtalmiques traitant l'hypertention oculaire

Info

Publication number
MA28017A1
MA28017A1 MA28846A MA28846A MA28017A1 MA 28017 A1 MA28017 A1 MA 28017A1 MA 28846 A MA28846 A MA 28846A MA 28846 A MA28846 A MA 28846A MA 28017 A1 MA28017 A1 MA 28017A1
Authority
MA
Morocco
Prior art keywords
sub
hypertention
ophthalmic compositions
treating ocular
sup
Prior art date
Application number
MA28846A
Other languages
English (en)
French (fr)
Inventor
Meng Hsin Chen
James B Doherty
Luping Liu
Swaminathan Natarajan
Robert M Tynebor
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA28017A1 publication Critical patent/MA28017A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503Five-membered rings
    • C07F9/65031Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA28846A 2003-09-04 2006-03-01 Compositions ophtalmiques traitant l'hypertention oculaire MA28017A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50009503P 2003-09-04 2003-09-04

Publications (1)

Publication Number Publication Date
MA28017A1 true MA28017A1 (fr) 2006-07-03

Family

ID=34312181

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28846A MA28017A1 (fr) 2003-09-04 2006-03-01 Compositions ophtalmiques traitant l'hypertention oculaire

Country Status (20)

Country Link
US (1) US7410992B2 (ru)
EP (1) EP1663987B1 (ru)
JP (1) JP4546961B2 (ru)
KR (1) KR20060090801A (ru)
CN (2) CN102558231B (ru)
AT (1) ATE425971T1 (ru)
AU (1) AU2004272546B2 (ru)
BR (1) BRPI0414102A (ru)
CA (1) CA2537410C (ru)
DE (1) DE602004020079D1 (ru)
EC (1) ECSP066404A (ru)
IL (1) IL174068A0 (ru)
IS (1) IS8306A (ru)
MA (1) MA28017A1 (ru)
MX (1) MXPA06002515A (ru)
NO (1) NO20061505L (ru)
NZ (1) NZ545401A (ru)
RU (1) RU2006110625A (ru)
WO (1) WO2005026128A1 (ru)
ZA (1) ZA200601321B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1988903A (zh) * 2004-07-20 2007-06-27 默克公司 用于治疗高眼压症的眼用组合物
JP5747392B2 (ja) * 2010-03-26 2015-07-15 ガルデルマ・リサーチ・アンド・デヴェロップメント 毛細血管拡張症の安全かつ有効な治療のための改善された方法および組成物
WO2012046708A1 (ja) * 2010-10-08 2012-04-12 Axis株式会社 線維筋痛症の診断剤,診断方法及び治療剤
WO2012139495A1 (en) * 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
CN110256314B (zh) * 2019-06-28 2020-12-15 南京林业大学 一种β-芳基酮类化合物的制备方法及其产品

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) * 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
WO1989010757A1 (en) 1988-05-10 1989-11-16 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis New ophthalmic preparation for treating glaucoma
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
ES2062102T5 (es) * 1988-09-06 2004-12-01 Pharmacia Ab Derivados de prostaglandinas para el tratamiento de glaucoma o hipertension ocular.
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
EP0724443A4 (en) 1993-06-08 1997-09-10 Vide Pharmaceuticals METHOD AND PREPARATIONS FOR LOWERING THE EYE PRESSURE
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5573758A (en) * 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US5925342A (en) * 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
WO2000015608A1 (fr) 1998-09-14 2000-03-23 Ono Pharmaceutical Co., Ltd. Derives e de phenyl-prostaglandine a substitution-φ et medicaments les contenant comme ingredient actif
DE19846514A1 (de) * 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
MXPA02006322A (es) 1999-12-22 2002-12-13 Pfizer Prod Inc Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
DE60135972D1 (de) * 2000-01-18 2008-11-13 Merck & Co Inc Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
PL358481A1 (en) 2000-03-17 2004-08-09 Alcon Inc. 6-hydroxy-indazole derivatives for treating glaucoma
EP1186287A1 (en) 2000-03-31 2002-03-13 Toray Industries, Inc. Hair growth or hair formation controlling agents
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
MXPA03004623A (es) 2000-11-27 2003-09-05 Pfizer Prod Inc Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
JP2005532363A (ja) * 2002-06-14 2005-10-27 メルク エンド カムパニー インコーポレーテッド 高眼圧を治療するための眼用組成物
US7528163B2 (en) * 2002-11-08 2009-05-05 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CA2537430A1 (en) * 2003-09-04 2005-03-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension

Also Published As

Publication number Publication date
EP1663987A1 (en) 2006-06-07
AU2004272546A1 (en) 2005-03-24
CA2537410C (en) 2009-08-11
US7410992B2 (en) 2008-08-12
IL174068A0 (en) 2006-08-01
NZ545401A (en) 2008-10-31
RU2006110625A (ru) 2006-08-10
EP1663987B1 (en) 2009-03-18
JP4546961B2 (ja) 2010-09-22
JP2007504233A (ja) 2007-03-01
NO20061505L (no) 2006-04-27
MXPA06002515A (es) 2006-06-20
CN1845904A (zh) 2006-10-11
WO2005026128A1 (en) 2005-03-24
BRPI0414102A (pt) 2006-10-31
ATE425971T1 (de) 2009-04-15
IS8306A (is) 2006-02-16
DE602004020079D1 (de) 2009-04-30
CN102558231B (zh) 2015-05-27
CN102558231A (zh) 2012-07-11
ECSP066404A (es) 2006-09-18
ZA200601321B (en) 2007-05-30
KR20060090801A (ko) 2006-08-16
AU2004272546B2 (en) 2007-10-18
US20070010491A1 (en) 2007-01-11
CA2537410A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
DE60307607D1 (de) Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
BR0014596A (pt) Derivado de pirimidina, uso do mesmo, composição farmacêutica, e, método de tratar doenças ou condições médicas mediadas por citocinas
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
WO2004103279A3 (en) 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
TW200740760A (en) Malonamide derivatives
TW200501949A (en) Ophthalmic compositions for treating ocular hypertension
WO2005020917A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2002009702A3 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
SE0402925D0 (sv) Novel Compounds
EP4574822A3 (en) Compounds and compositions for use in treating skin disorders
DE69008142D1 (de) 4-Substituierten Imidazolen zur Senkung des intraokularen Druckes.
DE69930271D1 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
DE60003435D1 (de) Neue 2-decarboxy-2-phosphinico prostaglandin f analoge
MX2007006504A (es) Derivados de malonamida como inhibidores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer.
WO2007025897A3 (en) Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
MA28017A1 (fr) Compositions ophtalmiques traitant l'hypertention oculaire
WO2003057213A3 (en) Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
CA2534634A1 (en) Azolidinecarbonitriles and their use as dpp-iv inhibitors
DE60135972D1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
AU2012237066B2 (en) Pharmaceutical composition for preventing or treating macular degeneration
DE69518706D1 (de) Verwendung von Diphenylethanderivaten zur Herstellung eines Arzneimittels zur Behandlung von Glaukom
SE0104333D0 (sv) Therapeutic agents